A Study of Tivozanib in Combination With Durvalumab in Subjects With Advanced Hepatocellular Carcinoma

NCT03970616 · clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
27
Enrollment
INDUSTRY
Sponsor class

Stopped The study was terminated due to regulatory approval of newer therapeutic options and slower than anticipated accrual.

Conditions

Interventions

Sponsor

AVEO Pharmaceuticals, Inc.

Collaborators